Concentra Group Holdings Parent, Inc. (CON): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 consultingagreementdated.htm EX-10.1 consultingagreementdated 1 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”), dated as of July 6, 2026, is made and entered into by and between John R. Anderson, D.O. (“Consultant”) and Concentra Health Services, Inc. (“Co
How this was made
The 30-second read
Why it matters
This is a governance and compensation disclosure. It may affect internal continuity of clinical strategy and medical affairs through a consulting bridge, but it does not provide new operating metrics or financial guidance.
Market read
Traders may treat this as a routine executive transition with limited immediate valuation impact, unless they believe the medical officer’s expertise is pivotal to near-term regulatory or clinical initiatives.
What to watch
Continued vesting of unvested restricted stock and the specific hourly consulting cap (10 hours/week) could matter for compensation expense modeling, but the filing provides no aggregate cost estimate.
Background
The SEC 8-K Item 5.02 describes departure/appointment and compensatory arrangements, including a one-year post-retirement consulting agreement and equity award forfeiture/vesting modifications.
Ticker impact
Concentra discloses an 8-K Item 5.02 consulting arrangement tied to the retirement of its Executive Vice President and Chief Medical Officer, effective Dec. 31, 2026.
Likely low immediate price impact; any reaction would be muted unless investors view the transition as material to medical strategy or regulatory execution.
The disclosed terms focus on post-retirement consulting services, hourly compensation, and continued vesting mechanics for existing equity awards, without new financial guidance, contracts, or litigation outcomes.
Market effects
Minimal read-across to the healthcare services sector; this is an internal executive transition rather than a sector-wide regulatory or operational change.
No clear regional market implications from the disclosed content.
No global relevance indicated; the matter is company-specific governance and compensation.
Counterpoint
Investors could still re-rate the stock if the departing medical officer’s role is viewed as critical to clinical strategy or regulatory matters, even though the filing does not quantify performance impact.
Key entities
- issuerConcentra Group Holdings Parent, Inc.
Subject of the SEC 8-K, disclosing director/officer changes and compensatory arrangements via a consulting agreement and equity award vesting terms.
- executiveJohn R. Anderson, D.O.
Retiring Executive Vice President and Chief Medical Officer effective Dec. 31, 2026, then appointed as an independent consultant effective Jan. 1, 2027.
